100 participants
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-05-27
- Start Date:
- 2026-07-15
- Completion:
- 2029-02-28
Conditions
- Multiple Sclerosis
Interventions
- DRUG
No Results Yet